Authors
Malcolm D Mason, Wendy R Parulekar, Matthew R Sydes, Michael Brundage, Peter Kirkbride, Mary Gospodarowicz, Richard Cowan, Edmund C Kostashuk, John Anderson, Gregory Swanson, Mahesh KB Parmar, Charles Hayter, Gordana Jovic, Andrea Hiltz, John Hetherington, Jinka Sathya, James BP Barber, Michael McKenzie, Salah El-Sharkawi, Luis Souhami, PD John Hardman, Bingshu E Chen, Padraig Warde
Publication date
2015/7/1
Journal
Journal of Clinical Oncology
Volume
33
Issue
19
Pages
2143-2150
Publisher
American Society of Clinical Oncology
Description
Purpose
We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we report the prespecified final analysis of this randomized trial.
Patients and Methods
NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110 was a randomized controlled trial of patients with locally advanced prostate cancer. Patients with T3-4, N0/Nx, M0 prostate cancer or T1-2 disease with either prostate-specific antigen (PSA) of more than 40 μg/L or PSA of 20 to 40 μg/L plus Gleason score of 8 to 10 were randomly assigned to lifelong ADT alone or to ADT+RT. The RT dose was 64 to 69 Gy in 35 to 39 fractions to the prostate and pelvis or prostate alone. Overall survival was compared using a log-rank test stratified for prespecified variables.
Results
One thousand two hundred five patients were …
Scholar articles
MD Mason, WR Parulekar, MR Sydes, M Brundage… - Journal of Clinical Oncology, 2015